image description

Tag: BMS-986165

Lupus Nephritis: A Major Focus at the Lupus Research Alliance

Updated March, 2022 Developing safe and effective treatments for lupus nephritis has been an urgent and long-standing goal in the lupus community. As the leading private funding agency for lupus research, the LRA and its legacy organizations have dedicated significant focus and resources towards addressing this continued challenge, awarding over 40 grants to address this […] Read More

Lupus Research Alliance Applauds Phase III Trial Results for Potential Lupus Nephritis Treatment

December 4, 2019 The Lupus Research Alliance congratulates Aurinia Pharmaceuticals on achieving the first positive Phase III trial results for an urgently needed treatment for lupus nephritis. The company’s investigational drug voclosporin showed positive effectiveness and good safety for treating lupus nephritis in combination with standard therapy. “Lupus nephritis is one of the most common […] Read More

Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus

New York, NY– June 27, 2019.  The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […] Read More

Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial

April 26, 2018 Lupus Research Alliance and Lupus Therapeutics collaborate with Bristol-Myers Squibb on a New Lupus Trial The Lupus Research Alliance today announced a collaboration between its newly formed affiliate, Lupus Therapeutics, and the pharmaceutical company, Bristol-Myers Squibb (BMS), to test a novel investigational drug, BMS-986165, as a potential new therapy for lupus. The […] Read More
Stay informed about events, research developments, and ways you can help. Sign up for updates